Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7752W HIGH $480.00
Volume
9.07 K
Value Traded
43.76 K
Short % Float
-
+9.67%Week
+580.67%1 Month
+230.65%3 Month
-53.99%6 Month
-99.78%5 Year
-99.78%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
-
EPS (TTM)
-24.14
P/E Ratio
-
Ent. Value
-8.96 M
Total Shares
-
Float Shares
420.00 K
Insiders
-
Institutions
1.21%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CMND Catalyst Timeline
Dated clinical, regulatory and corporate events for Clearmind Medicine Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Clearmind Medicine Inc.
316Total events
6Upcoming
48Tier-1 (high impact)
2021 to 2026Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T1Breakthrough Therapy Designation
Subscribe to view catalyst details
Event history 50
▲Patent Granted3-MMCIP / Competition
Patent application published in Japan covering 3-MMC compositions and methods for treating dyskinesia, including combinations with PEA
dyskinesiasource ↗
●Timing GuidancePresentation
Clearmind submits recommendations to FDA on psychedelic drug therapeutic use
Alcohol Use Disordersource ↗
●Timing GuidancePresentation
Clearmind Chief of Global Impact briefs FDA-convened federal panel on patient access
●FDA Feedback ReceivedFDA Meeting
Clearmind testified at FDA psychedelic hearing following FDA invitation
▲Enrollment UpdateCMND-100Trial
First patients with AUD enrolled in CMND-100 clinical trial
Alcohol Use Disordersource ↗
▲First Patient DosedCMND-100Trial
First time CMND-100 administered to a patient with AUD
Alcohol Use Disordersource ↗
▲Trial InitiationCMND-100Trial
Yale IRB approval enables patient recruitment for Parts B and C of CMND-100 trial
Alcohol Use Disordersource ↗
▲Primary Endpoint MetCMND-100Clinical Data
Part A achieved primary endpoint of safety and tolerability
Alcohol Use Disordersource ↗
▲Enrollment UpdateCMND-100Trial
Yale IRB approval enables patient recruitment for Parts B and C at Yale School of Medicine
Alcohol Use Disordersource ↗
▲Ethics Committee ApprovalCMND-100Trial
Yale University IRB approves patient recruitment for Parts B and C of CMND-100 Phase I/II trial
Alcohol Use Disordersource ↗
◆AcquisitionCorporate
Clearmind Medicine signs definitive agreement to acquire 51% stake in Charging Robotics
▲Trial InitiationCMND-100Trial
Initiation of Phase IIa stage of Phase I/IIa trial for CMND-100
Alcohol Use Disordersource ↗
▲DSMB ReviewCMND-100Trial
DSMB recommended advancing to subsequent parts after Part A review
Alcohol Use Disordersource ↗
◆AcquisitionCorporate
Clearmind signs LOI to acquire 51% stake in EV wireless charging company
▲Primary Endpoint MetCMND-100Clinical Data
Part A dose escalation achieved primary endpoint of safety and tolerability
Alcohol Use Disorder (AUD)source ↗
▲Enrollment CompleteCMND-100Trial
Enrollment completed for Part A with 24 participants across four cohorts
Alcohol Use Disorder (AUD)source ↗
▲Trial CompletionCMND-100Trial
Completed treatment for all 24 participants in Part A of Phase I/II trial
Alcohol Use Disordersource ↗
●Composition Patent FiledIP / Competition
Filed patent application with Hong Kong Patent Office for novel psychedelic compounds targeting PTSD
Post-Traumatic Stress Disorder (PTSD) and other mental health disorderssource ↗
▲Preclinical PoCMEAIPreclinical
Positive ex vivo mucoadhesion results for intranasal MEAI formulation
Alcohol Use Disordersource ↗
●Other Regulator MilestoneEx-US Regulatory
Clearmind submitted formal response to HHS RFI about MEAI's potential for addiction treatment
addictionsource ↗
●Other Regulator MilestoneCMND-100Ex-US Regulatory
Submitted formal response to HHS RFI about MEAI/CMND-100 for addiction treatment
Alcohol Use Disordersource ↗
▲Preclinical PoCMEAIPreclinical
Successful formulation feasibility study for intranasal delivery of MEAI
alcohol use disordersource ↗
●Timing GuidancePresentation
Clearmind responds to HHS Request for Information under Great American Recovery Initiative
Alcohol Use Disordersource ↗
●Timing GuidanceMEAIPresentation
Clearmind responds to HHS RFI under Great American Recovery Initiative highlighting MEAI
Alcohol Use Disordersource ↗
▲Patent GrantedMEAIIP / Competition
US Patent No. 12,357,590 'BINGE BEHAVIOR REGULATORS' granted by USPTO
binge behaviors (excessive drinking, eating, compulsive disorders)source ↗
▲Patent GrantedMEAIIP / Competition
U.S. Patent No. 12,357,590 granted for MEAI and related compounds
binge behaviorssource ↗
▲Enrollment CompleteCMND-100Trial
Completed treatment for all 24 participants in Part A of Phase I/II trial
Alcohol Use Disordersource ↗
▲Patent GrantedMEAIIP / Competition
U.S. Patent No. 12,350,242 granted for MEAI as binge behavior regulator
binge behaviors (excessive drinking, eating, gambling)source ↗
▲Enrollment CompleteCMND-100Trial
Completed dosing for all 24 participants in Cohorts 1-4 of Part A
Alcohol Use Disordersource ↗
▼Equity OfferingCorporate
Additional convertible note purchase of $1,000,000 principal amount
◆Oral PresentationCMND-100Presentation
Inside MEAI Webinar: New Insights from CMND-100 Psychedelic Clinical Trial
Alcohol Use Disordersource ↗
▲Patent GrantedMEAIIP / Competition
Japanese Patent Application Published for MEAI for Depression
depressionsource ↗
▲IND ClearanceCMND-100IND
Johns Hopkins IRB approval to advance CMND-100 Phase I/II trial to Parts B and C
Alcohol Use Disordersource ↗
▲Partnership / LicenseMEAICorporate
Signed research agreement with Yissum to study MEAI in combination and sequencing with tirzepatide
obesitysource ↗
◆Preclinical PoCMEAIPreclinical
12-month preclinical study evaluating MEAI in combination and sequencing with tirzepatide in DIO mice
obesitysource ↗
▲First Patient DosedCMND-100Trial
Two additional participants dosed in fourth cohort
Alcohol Use Disordersource ↗
▲Enrollment MilestoneCMND-100Trial
20 participants treated across all cohorts
Alcohol Use Disordersource ↗
▲Patent GrantedIP / Competition
Filing of European patent application for novel psychedelic compounds for PTSD
PTSDsource ↗
●Composition Patent FiledIP / Competition
European patent application filed for novel psychedelic compounds for PTSD
PTSDsource ↗
▲Primary Endpoint MetCMND-100Clinical Data
CMND-100 meets primary safety and tolerability endpoint in Phase I/IIa AUD trial
Alcohol Use Disordersource ↗
▲FDA Feedback ReceivedFDA Meeting
President Trump's Executive Order directing FDA to prioritize review for certain psychedelic drugs designated as breakthrough therapies
serious mental illnesssource ↗
▲DSMB ReviewCMND-100Trial
DSMB positive recommendation to continue Phase I/IIa trial of CMND-100
Alcohol Use Disordersource ↗
▲Enrollment MilestoneCMND-100Trial
Third cohort completed; proceeding to fourth cohort at 160mg dose
Alcohol Use Disordersource ↗
▲Primary Endpoint MetCMND-100Clinical Data
CMND-100 meets primary safety and tolerability endpoint in Phase I/IIa trial
Alcohol Use Disordersource ↗
▲Primary Endpoint MetCMND-100Clinical Data
Primary safety endpoint met in first three cohorts
Alcohol Use Disordersource ↗
Past FDA Catalysts and PDUFA Decisions
How CMND actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-10 | CMND-100 | Phase 1/2a data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D22 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 89%
Micro Cap(rank 588 of 660)
Percentile Rank
Clearmind Medicine Inc. faces pipeline headwinds (22/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CMND-100 Small moleculeNCT05913752 | Alcohol Use Disorder | Phase 1 | RECRUITING | 84 | Dec 31, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every CMND program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CMND-100 | Alcohol Use Disorder | Phase 1/2 | 2026-07-30 | All 24 participants completed the trial without serious adverse events.Read More | Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical TrialRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HRT FINANCIAL LP10% Owner | Sell | -22,139 81,353 held | $3.31 | 06/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CMND
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CMND for Q2 2026. | ||||
CMND Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CMND ranks across every disease it competes in
Competitive Position is a premium feature
See how CMND ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCMND News
CMND▲ +3.8%today
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
Clearmind Medicine Inc. announced the publication of a patent application in Japan for a treatment targeting dyskinesia, utilizing 3-Methylmethcathinone (3-MMC) and its combination with Palmitoylethanolamide (PEA). This development is part of Clearmind's collaboration with NeuroThera Labs, aimed at enhancing their therapeutic offerings. The company emphasizes its commitment to building a strong intellectual property portfolio around its innovative treatments.
Read more →CMND▲ +13%on this newsshared move
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
Clearmind Medicine Inc. has submitted recommendations to the FDA regarding the therapeutic use of non-hallucinogenic neuroplastogens for Alcohol Use Disorder. The company emphasizes the need for new regulatory pathways and self-administration options to enhance patient access. Their clinical trials have shown potential benefits of these compounds without the hallucinogenic effects of traditional psychedelics.
Read more →CMND▲ +8.8%on this news
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
Clearmind Medicine Inc. has published three patent applications in the U.S. covering combinations of LSD, ketamine, and ibogaine with N-acylethanolamines. These applications target therapeutic uses for mental health disorders, including depression and PTSD. The company aims to develop safer treatment paradigms with lower doses while maintaining efficacy, supported by its collaboration with NeuroThera Labs.
Read more →CMND▲ +6.5%on this news
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
Clearmind Medicine recently participated in a historic FDA hearing on psychedelic drugs, where Chief of Global Impact Mary-Elizabeth Gifford presented insights from their clinical trials. The hearing focused on patient access and the therapeutic potential of non-hallucinogenic psychedelics. Clearmind's drug candidate, MEAI, is currently in Phase 2a trials for Alcohol Use Disorder, aiming to provide scalable treatment options.
Read more →CMNDClearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
Clearmind Medicine Inc. has enrolled the first patients in its CMND-100 clinical trial targeting Alcohol Use Disorder (AUD). This marks a significant milestone for the company as it evaluates the safety and efficacy of its psychedelic-based treatment. The trial aims to assess CMND-100's pharmacokinetics and tolerability, with positive enrollment trends noted by the CEO.
Read more →CMND▼ -11.2%on this newsshared move
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results
Clearmind Medicine has received approval from Yale University's IRB to begin patient recruitment for Parts B and C of its Phase I/II trial for CMND-100, following positive safety results from Part A. The trial aims to evaluate the drug's safety and tolerability in treating Alcohol Use Disorder. This approval allows Clearmind to expand recruitment efforts at Yale, joining other leading medical centers already involved in the study.
Read more →CMND▼ -31.8%on this news· ran to -42% by day 3shared move
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
Clearmind Medicine Inc. has signed a definitive agreement to acquire a 51% stake in Charging Robotics, a company specializing in wireless charging solutions for automated parking and autonomous vehicles. The acquisition, valued at $2.5 million, includes a $1.5 million loan to support Charging Robotics. The closing is expected during the week of September 7, 2026, pending certain conditions.
Read more →CMND▼ -5.7%on this news· ran to -40% by day 3shared move
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
Clearmind Medicine Inc. has initiated Phase IIa of its clinical trial for CMND-100, targeting Alcohol Use Disorder (AUD). The trial has enrolled six patients across two medical centers in Israel. Following a successful safety evaluation in healthy volunteers, the trial aims to assess the safety and efficacy of CMND-100 in individuals with moderate-to-severe AUD.
Read more →CMNDClearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
Clearmind Medicine Inc. has published a patent application for a novel MDMA and N-acylethanolamines combination aimed at treating PTSD and other disorders. This development coincides with the FDA's new guidance on psychedelic drug regulation, which includes MDMA. The collaboration with NeuroThera Labs enhances the therapeutic potential of MDMA while addressing dosing and side effects.
Read more →CMND▲ +12.1%on this news
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
Clearmind Medicine has received approval from the Independent Data and Safety Monitoring Board to advance its Phase I/II clinical trial of CMND-100 for Alcohol Use Disorder. Following the successful completion of Part A, which demonstrated a favorable safety profile, the trial will now evaluate CMND-100 in patients with moderate to severe AUD. This advancement represents a significant step in developing new treatment options for AUD.
Read more →CMNDClearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery
Clearmind Medicine announced positive results from its intranasal MEAI formulation study, confirming enhanced nasal retention without compromising drug delivery. The findings support the continued development of MEAI as a therapeutic candidate for mental health disorders, including alcohol use disorder. The study demonstrated that the formulation maintains effective permeation characteristics while achieving prolonged contact with nasal tissue.
Read more →CMNDClearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study
Clearmind Medicine has received DSMB approval to progress its Phase I/II trial of CMND-100 for Alcohol Use Disorder (AUD). This approval follows successful safety results from Part A, allowing the trial to evaluate the drug in patients with AUD. The study aims to assess safety, tolerability, and early efficacy signals in reducing alcohol consumption.
Read more →CMNDClearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company
Clearmind Medicine Inc. has signed a non-binding Letter of Intent to acquire a 51% stake in a company specializing in intelligent EV wireless charging solutions. The acquisition, valued at $2.5 million, aims to enhance Clearmind's portfolio and improve operational efficiency in automated parking systems. A loan of $1.5 million will also be extended to the acquired company, subject to certain closing conditions.
Read more →CMND▲ +11%on this newsshared move
Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial
Clearmind Medicine Inc. announced positive safety results from Part A of its Phase I/II clinical trial for CMND-100, a treatment for Alcohol Use Disorder. All 24 participants completed the trial without serious adverse events, and the drug showed consistent tolerability across ascending doses. The study's success reinforces the potential of CMND-100 as a non-hallucinogenic treatment option.
Read more →CMND▼ -9.9%on this newsshared move
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial
Clearmind Medicine Inc. has successfully completed Part A of its Phase I/II trial for CMND-100, aimed at treating Alcohol Use Disorder. All 24 participants finished treatment as per the study protocol. The company is now reviewing the data and plans to advance to the next stage if results are favorable. The trial is conducted under FDA oversight at prominent medical institutions.
Read more →CMNDClearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
Clearmind Medicine Inc. has filed a patent application in Hong Kong for novel psychedelic compounds aimed at treating PTSD and other mental health disorders. This move is part of a global licensing agreement with Yissum Research Development Company, enhancing Clearmind's intellectual property portfolio. The global PTSD treatment market is expected to grow from $18.5 billion in 2025 to $30.2 billion by 2035, indicating a significant commercial opportunity for the company.
Read more →CMNDClearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
Clearmind Medicine Inc. has acknowledged recent regulatory advancements that support the development of psychedelic-based therapies for mental health and addiction. Key developments include FDA guidance on psychedelic clinical investigations and collaborative initiatives with various health agencies. The company's lead candidate, CMND-100, is currently undergoing Phase I/IIa trials for Alcohol Use Disorder.
Read more →CMND▲ +7.6%on this newsshared move
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
Clearmind Medicine Inc. reported positive results from its study on the intranasal formulation of MEAI, showing enhanced nasal retention compared to standard solutions. This advancement is crucial for maximizing the therapeutic potential of MEAI in treating Alcohol Use Disorder. The study highlights the benefits of the mucoadhesive polymer system, which improves drug delivery performance.
Read more →CMNDClearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
Clearmind Medicine Inc. has shared positive insights from its ongoing Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. Investigators highlighted the compound's non-hallucinogenic nature, which allows for easier treatment administration. The trial has shown a promising safety profile and effective recruitment of participants. The company aims to develop innovative therapies for under-treated health issues.
Read more →CMNDClearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative
Clearmind Medicine Inc. has submitted a response to the U.S. Department of Health and Human Services regarding its innovative treatment for Alcohol Use Disorder (AUD) using its non-hallucinogenic neuroplastogen, CMND-100. The submission aligns with the Great American Recovery Initiative, emphasizing the need for effective addiction treatments. Clearmind's approach aims to provide scalable and accessible solutions for those affected by AUD.
Read more →About Clearmind Medicine Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next CMND catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime